Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

The Lancet · 1998 · 20.1K citations

Medicine, Endocrinology, Pharmacotherapy +13

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

R. C. Turner, Charles Fox, Matthews et al. · The Lancet · 1998 · 8.4K citations

Medicine, Endocrinology, Pharmacotherapy +15

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.

Luciano Rossetti, Douglas J. Smith, Gerald I. Shulman et al. · Journal of Clinical Investigation · 1987 · 808 citations · Full text

Medicine, Endocrinology, Pharmacology +16

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

James F. List, Vincent Woo, Enrique Morales et al. · Diabetes Care · 2008 · 696 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Wei Meng, Bruce A. Ellsworth, Alexandra A. Nirschl et al. · Journal of Medicinal Chemistry · 2008 · 628 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17